 TORONTO, June 20, 2019 PRNewswire -- Edesa Biotech, Inc. Nasdaq: EDSA, a clinical-stage biopharmaceutical company, reported today that the U.S. Food and Drug Administration has notified the company that it may proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which Edesa is developing as a potential treatment for chronic allergic contact dermatitis. The FDA safe to proceed letter formally approves the companys Phase 2b clinical protocol and authorizes the company to begin its clinical investigation. 